Literature DB >> 18339899

Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma.

Jessica Dal Col1, Paola Zancai, Liliana Terrin, Massimo Guidoboni, Maurilio Ponzoni, Alessandro Pavan, Michele Spina, Stefano Bergamin, Silvana Rizzo, Umberto Tirelli, Anita De Rossi, Claudio Doglioni, Riccardo Dolcetti.   

Abstract

Functional characterization of signaling pathways that critically control mantle cell lymphoma (MCL) cell growth and survival is relevant to designing new therapies for this lymphoma. We herein demonstrate that the constitutive activation of Akt correlates with the expression of the phosphorylated, inactive form of PTEN. Phosphatidyl-inositol-3 kinase (PI3-K)/Akt or mammalian target of rapamycin (mTOR) inhibition decreased the growth of both primary MCL cultures and established cell lines and antagonizes the growth-promoting activity of CD40 triggering and IL-4. These effects are mediated by nuclear accumulation of the p27(Kip1) inhibitor induced by down-regulation of the p45(Skp2) and Cks1 proteins, which target p27(Kip1) for degradation. Moreover, Akt inhibition down-regulated cyclin D1 by promoting its proteasome-dependent degradation driven by GSK-3. Intriguingly, mTOR inhibition affected cyclin D1 proteolysis only in MCL cells in which GSK-3 is under the direct control of mTOR, suggesting that different MCL subsets could be differently responsive to mTOR inhibition. Finally, PI3-K/Akt inhibitors, but not rapamycin, induced variable levels of caspase-dependent apoptosis and reduced telomerase activity. These results indicate that Akt and mTOR activation have distinct functional relevance in MCL and suggest that targeting Akt may result in more effective therapeutic effects compared with mTOR inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339899     DOI: 10.1182/blood-2007-07-103481

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

Review 1.  Utility of mTOR inhibition in hematologic malignancies.

Authors:  Anas Younes; Nousheen Samad
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

Review 3.  Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors:  Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Expert Opin Investig Drugs       Date:  2018-06-07       Impact factor: 6.206

4.  Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.

Authors:  Debasmita Roy; Dirk P Dittmer
Journal:  Am J Pathol       Date:  2011-08-03       Impact factor: 4.307

Review 5.  Phosphoinositide 3-kinase inhibitors in lymphoma.

Authors:  Emily Curran; Sonali M Smith
Journal:  Curr Opin Oncol       Date:  2014-09       Impact factor: 3.645

6.  Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells.

Authors:  Rekha Rao; Pearl Lee; Warren Fiskus; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Kate Buckley; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul Joshi; Sunil Upadhyay; Jianguo Tao; Eduardo Sotomayor; Kapil N Bhalla
Journal:  Cancer Biol Ther       Date:  2009-07       Impact factor: 4.742

Review 7.  Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.

Authors:  Jason R Westin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-02-07

8.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2008-09       Impact factor: 0.196

9.  Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.

Authors:  Nousheen Samad; Anas Younes
Journal:  Onco Targets Ther       Date:  2010-09-07       Impact factor: 4.147

10.  Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.

Authors:  Li Wang; Wen-Yu Shi; Zhi-Yuan Wu; Mariana Varna; Ai-Hua Wang; Li Zhou; Li Chen; Zhi-Xiang Shen; He Lu; Wei-Li Zhao; Anne Janin
Journal:  J Hematol Oncol       Date:  2010-09-09       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.